We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomérieux Launches Free Mobile App to Aid Clinicians in Emergency and Critical Care Diagnostics

By HospiMedica International staff writers
Posted on 04 Mar 2022
Print article
Image: MYACUTECASE (Photo courtesy of bioMérieux)
Image: MYACUTECASE (Photo courtesy of bioMérieux)

A free mobile application aims to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics. In hospitals, particularly for emergency cases, diagnostic options can be limited for patients with acute and complex pathologies. Clinicians need to rapidly and accurately assess and identify the correct therapeutic protocol for each patient. With the vast array of biomarkers available today, interpretation can be challenging but crucial to optimize patient care and help save lives. For correct interpretation of a particular in vitro diagnostics (IVD) test, it is of paramount importance to align the medical diagnostic and management decisions with corresponding guidelines, expert recommendations and best practices.

bioMérieux (Marcy-l'Étoile, France) has developed the first of a kind mobile application, MYACUTECASE that serves as an aid in the interpretation of VIDAS emergency and critical care biomarker tests. The first version of bioMérieux’s easy-to-use mobile application addresses four emergency and critical care assays, namely VIDAS D-Dimer Exclusion II, VIDAS NT-proBNP2, VIDAS B.R.A.H.M.S PCT, and VIDAS High sensitive Troponin I.

Through the application’s educational material, hospitals will be able to support continuous healthcare education through on-demand high medical value content regarding targeted disease states, corresponding diagnostic pathways, relevant biomarkers and their use in various situations. It combines within the same digital tool the entire information that one finds in the test’s package insert, the information brochure, various peer-reviewed national and international guidelines, and other relevant material.

MYACUTECASETM is registered as IVD software and has been co-developed with experts and target users. More than 20 clinicians were involved in designing and approving MYACUTECASE. The application is now available on Apple App Store for free, both in French and in English, and it is planned to evolve by including other test parameters or languages. In the future it will also be compatible with other OS such as Android.

“With MYACUTECASE, our goal is to help clinicians choose the right biomarker tests to order for a particular patient and facilitate the interpretation of results,” said Mark Miller, Executive Vice President, Chief Medical Officer. “A rapid and easy access to testing and disease information, expert guidelines and best practices will allow them to improve patient care and potentially to save lives.”

“MYACUTECASE is a very innovative application that will help labs and clinicians working together but also clinicians better interpreting insights from VIDAS emergency testing,” added Pierre Boulud, Chief Operating Officer, Clinical Operations. “Our data insight solutions are a strategic component of our offering. They bring unique opportunities to leverage the quality of diagnostics to enhance its medical value for the benefit of patients.”

Related Links:
bioMérieux 

Gold Supplier
Creatinine Meter
StatSensor Xpress Creatinine Meter
New
Digital X-Ray Flat Panel Detector
2121DXV
New
Gynecological Examination & Treatment Chair
medi-matic
New
Chair Scale
seca 954

Print article
FIME - Informa

Channels

AI

view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: Electromagnetic cores precisely guide the array of nanozyme-bots as they target the site of fungal infection (Photo courtesy of University of Pennsylvania)

Nanorobots Guided by Magnets Capable of Rapid, Targeted Elimination of Fungal Pathogens

Fungal infections, particularly those caused by Candida albicans, present a significant health threat globally due to their resistance to current treatments. Although nanomaterials show potential as antifungal... Read more

Surgical Techniques

view channel
Image: The benchmark may be useful in identifying the best treatment hospital for patients with gallbladder cancer (Photo courtesy of Freepik)

First-Ever Standard for Gallbladder Cancer Surgery Could Improve Patient Outcomes

Gallbladder cancer (GBC) surgery is a technically demanding procedure that requires significant expertise to meet high-quality surgical standards. Despite this, subpar surgeries are common, highlighting... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.